6533b821fe1ef96bd127c36d

RESEARCH PRODUCT

United States and European Multicenter Prospective Study for the Analytical Performance and Clinical Validation of a Novel Sensitive Fully Automated Immunoassay for Calcitonin.

Juergen KratzschFriedhelm RaueJennifer A. SiposJoachim FeldkampS KargerTanja DianaMark A. LupoThomas E. DavisAlicia Algeciras-schimnichMatthew D. RingelGeorge J. KahalyJochem König

subject

AdultCalcitoninMalemedicine.medical_specialtyPercentileClinical Biochemistry030209 endocrinology & metabolismGastroenterologySensitivity and SpecificityThyroid carcinoma03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansClinical significanceProspective StudiesProspective cohort studyCalcium metabolismAutomation LaboratoryImmunoassaymedicine.diagnostic_testbusiness.industryBiochemistry (medical)ThyroidReproducibility of ResultsReference StandardsUnited StatesEuropeEndocrinologymedicine.anatomical_structureCalcitonin030220 oncology & carcinogenesisImmunoassayCalciumFemalebusiness

description

Abstract BACKGROUND The objective of this study is the validation and proof of clinical relevance of a novel electrochemiluminescence immunoassay (ECLIA) for the determination of serum calcitonin (CT) in patients with medullary thyroid carcinoma (MTC) and in different diseases of the thyroid and of calcium homeostasis. METHODS This was a multicenter prospective study on basal serum CT concentrations performed in 9 US and European referral institutions. In addition, stimulated CT concentrations were measured in 50 healthy volunteers after intravenous calcium administration (2.5 mg/kg bodyweight). RESULTS In total, 1929 patients and healthy controls were included. Limits of blank, detection, and quantification for the ECLIA were 0.3, 0.5, and 1 ng/L, respectively. Highest intra- and interassay coefficients of variation were 7.4% (CT concentration, 0.8 ng/L) and 7.0% (1.1 ng/L), respectively. Medians (interval) of serum CT concentrations in 783 healthy controls were 0.8 ng/L (<0.5–12.7) and 3 ng/L (<0.5–18) for females and males, respectively (97.5th percentile, 6.8 and 11.6 ng/L, respectively). Diagnostic sensitivity and specificity were 100%/97.1% and 96.2%/96.4%, for female/males, respectively. Patients (male/female) with primary hyperparathyroidism, renal failure, and neuroendocrine tumors showed CT concentrations >97.5th percentile in 33%/4.7%, 18.5%/10%, and 8.3%/12%, females/males, respectively. Peak serum CT concentrations were reached 2 min after calcium administration (161.7 and 111.8 ng/L in males and females, respectively; P < 0.001). CONCLUSIONS Excellent analytical performance, low interindividual variability, and low impact of confounders for increased CT concentrations in non-MTC patients indicate that the investigated assay has appropriate clinical utility. Calcium-stimulated CT results suggest good test applicability owing to low interindividual variability.

10.1373/clinchem.2016.270009https://pubmed.ncbi.nlm.nih.gov/28687633